Genetic Evidence for Causal Effects of Lipid-lowering Drug Targets onPrimary Sjögren's Syndrome Risk: A Mendelian Randomization Study
This study provides compelling evidence suggesting that lipid-lowering drugs may contribute to the risk of pSS, thus offering new insights for clinical intervention strategies.
Authors
- Yu‐Cui Li
- Zhiyuan Qiu (ORCID: https://orcid.org/0000-0002-8782-6758)
- Weiquan Liao
- Jingjing Xie (ORCID: https://orcid.org/0000-0003-4343-2519)
- Jianyong Zhang (ORCID: https://orcid.org/0009-0000-5645-0885)
- Lijuan Xiao (ORCID: https://orcid.org/0000-0002-8647-8296)
- Yongjie Guo
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Shenzhen Pingle Orthopedic Hospital (CN)
Publication Details
- Journal
- Current Pharmaceutical Biotechnology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.2174/0113892010387265250730110805
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 0.00